前列腺特异性膜抗原PET/CT在非前列腺恶性肿瘤中的诊疗应用
本文综述了68Ga-PSMA PET/CT在前列腺癌以外恶性肿瘤中的应用探索。PSMA在前列腺癌及多种非前列腺恶性肿瘤的肿瘤新生血管中表达,包括胶质瘤、肾细胞癌、分化型甲状腺癌、肺癌、乳腺癌及唾液腺肿瘤等。综述描述了PSMA PET/CT在这些肿瘤中的诊断与潜在治疗应用,并指出部分研究显示其影像结果优于18F-FDG PET/CT,同时需注意良性病变的PSMA摄取。
要点
- PSMA在多种非前列腺恶性肿瘤的肿瘤新生血管中表达,拓展了PSMA PET/CT的应用范围。
- 部分非前列腺肿瘤中PSMA PET/CT影像结果优于18F-FDG PET/CT。
- 分析PSMA PET/CT时需注意良性病变也可出现PSMA摄取。
核心结论
- PSMA PET/CT在非前列腺恶性肿瘤的诊断与潜在治疗应用中具有探索价值。
研究设计与样本
- 本文为综述,汇总了PSMA基于PET/CT在多种非前列腺恶性肿瘤影像诊断及潜在治疗应用方面的临床探索。
主要发现
- PSMA在胶质瘤、肾细胞癌、分化型甲状腺癌、肺癌、乳腺癌及唾液腺肿瘤等非前列腺恶性肿瘤的肿瘤新生血管中表达。
- 部分非前列腺恶性肿瘤中PSMA PET/CT的影像结果优于18F-FDG PET/CT。
临床怎么用
- 在非前列腺恶性肿瘤中可探索性使用PSMA PET/CT进行影像评估,并需注意良性病变的PSMA摄取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Gallium-prostate-specific membrane antigen (PSMA) PET/CT has evolved as a pivotal imaging modality for prostatic carcinoma. Prostate-specific membrane antigen (PSMA) is a zinc-dependent peptidase and a type II membrane protein that is expressed in prostate cancer and also tumor neovasculature of various nonprostatic malignancies. Recently, there have been many studies to demonstrate the expression of PSMA in vivo in nonprostatic malignancies like glioma, renal cell carcinoma, differentiated thyroid carcinoma, lung cancer, breast cancer, and salivary gland tumors, among others, and explore the diagnostic and therapeutic utility in these malignancies. While they have shown promising results with some even providing better imaging results than 18F-fluorodeoxyglucose PET/CT, it is important to evaluate the indications where PSMA PET/CT can be utilized efficiently. We must also be mindful of the benign conditions where PSMA uptake can be observed while we analyze the scans. In this review, we have described the clinical exploration of PSMA-based PET/CT in the imaging of various cancers and potential therapeutic applications.
引用
- Verma P, Basu S. Prostate-specific Membrane Antigen-PET/CT in Nonprostatic Malignancies: Potential Applications in Theranostics. Clin Nucl Med. 2025. PMID: 42081703. doi:10.1097/RLU.0000000000006171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。